Recent advances in obesity pharmacotherapy.
Obesity is considered a worldwide epidemic. Weight reduction by means of lifestyle changes is difficult to achieve, and pharmacotherapy is frequently needed. Although all currently approved anti-obesity agents have proven to be effective to achieve some degree of weight reduction and improve cardiometabolic risk factors, different compounds differ in their mechanism of action and safety profile. However, it is still difficult to achieve and maintain therapeutic objectives along time. The aim of the present article is to summarize the main characteristics of available anti-obesity agents and to explore novel agents that may provide significant clinical benefits in the future.
Mayer
Marcos A
MA
Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Junín, 956, (C1113AAD) Buenos Aires, Argentina. marcos.mayer@gmail.com
Höcht
Christian
C
Puyó
Ana
A
Taira
Carlos A
CA
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003503:Cyclobutanes / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D000077403:Orlistat; D010880:Piperidines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011720:Pyrazoles / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000077285:Rimonabant
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007783:Lactones; D010880:Piperidines; D011720:Pyrazoles; D000077403:Orlistat; D000077285:Rimonabant; C058254:sibutramine